CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF VIBRIO-CHOLERAE O139 BENGAL INFECTION IN NORTH-AMERICAN VOLUNTEERS

被引:55
作者
MORRIS, JG
LOSONSKY, GE
JOHNSON, JA
TACKET, CO
NATARO, JP
PANIGRAHI, P
LEVIN, MM
机构
[1] VET ADM MED CTR, PATHOL & LAB MED SERV, BALTIMORE, MD 21201 USA
[2] UNIV MARYLAND, SCH MED, CTR VACCINE DEV, BALTIMORE, MD 21201 USA
[3] UNIV MARYLAND, SCH MED, DEPT MED, BALTIMORE, MD 21201 USA
[4] UNIV MARYLAND, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21201 USA
[5] UNIV MARYLAND, SCH MED, DEPT PATHOL, BALTIMORE, MD 21201 USA
关键词
D O I
10.1093/infdis/171.4.903
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vibrio cholerae O139 Bengal has recently emerged as a cause of epidemic cholera in Asia. To evaluate clinical and immunologic responses to infection, V. cholerae O139 Bengal AI1837 was administered to healthy adult North American volunteers. Two of 4 persons ingesting 10(4) cfu became ill (incubation period, 48 h; mean diarrheal stool, 1873 g), as did 7 of 9 persons receiving 10(6) cfu (incubation period, 28 h; mean diarrheal stool, 4548 g). III volunteers did not demonstrate a vibriocidal antibody response to the challenge strain or other V. cholerae. Three months later, volunteers were rechallenged with the homologous O139 Bengal strain. Only 1 of 6 persons who had been ill on initial challenge had diarrhea, compared with 11 of 13 controls (P = .01; protective efficacy = 80%). V. cholerae O139 Bengal can cause severe diarrhea typical of cholera, with clinical characteristics and a dose-response similar to those seen with V. cholerae O1 E1 Tor. A moderately high level of protection against subsequent disease is provided by initial clinical infection.
引用
收藏
页码:903 / 908
页数:6
相关论文
共 48 条
[21]   CHOLERA [J].
KAPER, JB ;
MORRIS, JG ;
LEVINE, MM .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (01) :48-86
[22]   SAFETY AND IMMUNOGENICITY IN NORTH AMERICANS OF A SINGLE DOSE OF LIVE ORAL CHOLERA VACCINE CVD 103-HGR - RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CROSSOVER TRIAL [J].
KOTLOFF, KL ;
WASSERMAN, SS ;
ODONNELL, S ;
LOSONSKY, GA ;
CRYZ, SJ ;
LEVINE, MM .
INFECTION AND IMMUNITY, 1992, 60 (10) :4430-4432
[23]   GENETIC SUSCEPTIBILITY TO CHOLERA [J].
LEVINE, MM ;
NALIN, DR ;
RENNELS, MB ;
HORNICK, RB ;
SOTMAN, S ;
VANBLERK, G ;
HUGHES, TP ;
ODONNELL, S ;
BARUA, D .
ANNALS OF HUMAN BIOLOGY, 1979, 6 (04) :369-374
[24]   VOLUNTEER STUDIES OF DELETION MUTANTS OF VIBRIO-CHOLERAE O1 PREPARED BY RECOMBINANT TECHNIQUES [J].
LEVINE, MM ;
KAPER, JB ;
HERRINGTON, D ;
LOSONSKY, G ;
MORRIS, JG ;
CLEMENTS, ML ;
BLACK, RE ;
TALL, B ;
HALL, R .
INFECTION AND IMMUNITY, 1988, 56 (01) :161-167
[25]   DURATION OF INFECTION-DERIVED IMMUNITY TO CHOLERA [J].
LEVINE, MM ;
BLACK, RE ;
CLEMENTS, ML ;
CISNEROS, L ;
NALIN, DR ;
YOUNG, CR .
JOURNAL OF INFECTIOUS DISEASES, 1981, 143 (06) :818-820
[26]   EVALUATION IN HUMANS OF ATTENUATED VIBRIO-CHOLERAE EL-TOR OGAWA STRAIN TEXAS STAR-SR AS A LIVE ORAL VACCINE [J].
LEVINE, MM ;
BLACK, RE ;
CLEMENTS, ML ;
LANATA, C ;
SEARS, S ;
HONDA, T ;
YOUNG, CR ;
FINKELSTEIN, RA .
INFECTION AND IMMUNITY, 1984, 43 (02) :515-522
[27]   ENZYME-LINKED IMMUNOSORBENT-ASSAY TO MEASURE ANTIBODIES TO PURIFIED HEAT-LABILE ENTEROTOXINS FROM HUMAN AND PORCINE STRAINS OF ESCHERICHIA-COLI AND TO CHOLERA-TOXIN - APPLICATION IN SERODIAGNOSIS AND SEROEPIDEMIOLOGY [J].
LEVINE, MM ;
YOUNG, CR ;
BLACK, RE ;
TAKEDA, Y ;
FINKELSTEIN, RA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 21 (02) :174-179
[28]   IMMUNITY OF CHOLERA IN MAN - RELATIVE ROLE OF ANTIBACTERIAL VERSUS ANTI-TOXIC IMMUNITY [J].
LEVINE, MM ;
NALIN, DR ;
CRAIG, JP ;
HOOVER, D ;
BERGQUIST, EJ ;
WATERMAN, D ;
HOLLEY, HP ;
HORNICK, RB ;
PIERCE, NP ;
LIBONATI, JP .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1979, 73 (01) :3-9
[29]  
Levine MM, 1981, ACUTE ENTERIC INFECT, P443
[30]  
Levine Myron M., 1992, P285